Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

NLRP3 inflammasome inhibitors patented by Inflazome

March 16, 2021

Polycomb protein EED inhibitors identified at Shanghai Blueray Biopharma

March 16, 2021

Shanghai Zhimeng Biopharma discovers Toll-like receptor 8 agonists

March 16, 2021

NSD3 drives oncogenesis in LUSC, but may sensitize these tumors to bromodomain inhibition

March 15, 2021

IFN-mediated NAD depletion by upregulation of PARP9/10/14 sensitizes PDAC cells to NAMPT inhibitors

March 15, 2021

Galapagos presents TYK2 inhibitors

March 15, 2021

Inflazome synthesizes new NLRP3 inflammasome inhibitors

March 15, 2021

Hunan Warrant Pharmaceuticals patents Bcr-Abl1 and/or BTK inhibitors

March 15, 2021

Targeting membrane protein starves pancreatic tumors

March 15, 2021

Genfleet Therapeutics presents GTPase KRAS mutant inhibitors

March 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...